AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01111526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks.
Study NCT03108651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case
Description: Motivational message will be administrated.
Study NCT04991844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
Study NCT04176055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: haloperidol intervention
Study NCT04480697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo
Study NCT04051151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gameficiation
Description: Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
Study NCT02622724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Investigational drug
Study NCT02622724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for investigational drug
Study NCT03029650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transderm Scop®
Description: TDDS dosage is 1.5 mg/72 hrs
Study NCT03029650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transderm Scop®
Description: TDDS dosage is 1.5 mg/72 hrs
Study NCT03029650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous scopolamine hydrobromide
Description: 0.4 mg via intravenous injection
Study NCT03029650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous scopolamine hydrobromide
Description: 0.4 mg via intravenous injection
Study NCT02985268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip
Description: The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus \[degenerative MR\] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
Study NCT02985268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
Study NCT02985268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D
Description: Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
Study NCT03785496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
Study NCT02687230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-2163
Description: MVT-2163 is administered intravenously as a PET imaging agent
Study NCT02687230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
Study NCT03801525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form
Study NCT03801525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: * B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form
Study NCT03181763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given day after startle assessment
Study NCT03181763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Participant will receive 100 mg MDMA one day after startle assessment
Study NCT03181763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic startle
Description: Startle assessment
Study NCT03181763 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acoustic startle
Description: Startle assessment
Study NCT04424641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Description: GEN1044 will be administered intravenously in cycles of 21 days.
Study NCT00597038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib and Dacarbazine (DTIC)
Description: Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2.
Study NCT00221767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brindley technique (bladder system)
Description: Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
Study NCT03201549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral fructose challenge
Description: Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
Study NCT02351648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a transitional care model
Description: Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients
Study NCT00700817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, minimum 1500 mg daily
Study NCT02351648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients receive usual standard of care from the internal medicine team
Study NCT05251688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cryoanalgesia
Description: On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores.
Study NCT01354795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.EUS-FNA with or without suction
Description: During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
Study NCT00700817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg once daily, subcutaneous (under the skin) injection
Study NCT01354795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.Pushing the stylet or injecting air
Description: EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
Study NCT01184664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Varenicline + nicotine patch
Study NCT01184664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Varenicline + placebo patch
Study NCT02215148 — intervention group
Intervention type: DRUG
Intervention: Tolvaptan
Study NCT04272203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-184
Description: Intravenous (IV) infusion
Study NCT01333072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
Study NCT01333072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
Study NCT01453621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support
Description: Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
Study NCT03074864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
Study NCT03721302 — intervention group
Intervention type: OTHER
Intervention: Main study clinical sepsis
Description: No intervention-Observational study
Study NCT03721302 — intervention group
Intervention type: OTHER
Intervention: Microbiology sub study
Description: Analysis of Bacterial isolates
Study NCT02430805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dna extraction and genotyping
Description: blood and urine sample
Study NCT01184664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive a standard dose of varenicline (12 weeks).
Study NCT01184664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: All participants will receive a standard dose of varenicline (12 weeks).
Study NCT05929105 — intervention group
Intervention type: PROCEDURE
Intervention: artificial intelligence (AI)-assisted three-dimensional preoperative planning technology
Description: In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
Study NCT05929105 — intervention group
Intervention type: OTHER
Intervention: X-ray film template for 2D planning
Description: A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
Study NCT01352533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Running polypropylene closure
Description: Half of every wound will be closed with Standard of Care running polypropylene sutures
Study NCT01352533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesive (Derma-Bond)
Description: Approximately half of wounds will be randomized to be closed with tissue adhesive.
Study NCT02054013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization
Study NCT02054013 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: monopolar transurethral prostatectomy
Study NCT02264535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1mg/ml Ginkgolides Meglumine Injection
Study NCT02264535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg/ml Ginkgolides Meglumine Injection
Study NCT02264535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg/ml Ginkgolides Meglumine Injection
Study NCT00362830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine + ixabepilone
Description: solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
Study NCT02358850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco (Hydrocodone and Acetaminophen)
Description: Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
Study NCT02358850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet (Oxycodone and Acetaminophen)
Description: Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
Study NCT02358850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilaudid (hydromorphone)
Description: Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
Study NCT02358850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol (Acetaminophen)
Description: Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
Study NCT00965770 — intervention group
Intervention type: DEVICE
Intervention: Intrauterine device (IUD)
Description: Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
Study NCT01640873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8655
Description: Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
Study NCT01640873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
Study NCT02372591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study NCT02372591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study NCT03787654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total.
Study NCT03787654 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group.
Study NCT02372591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study NCT03240393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
Study NCT03844789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM
Description: Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM
Study NCT03844789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
Study NCT02658916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Same dose as corresponding CN002003 study panel.
Study NCT02948920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: 9 mg of ephedrine (3 ml)
Study NCT02948920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: 3 ml of normal saline
Study NCT01352533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular polyglactin-910 combined with tissue adhesive
Description: Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
Study NCT01525446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT with proton beam radiation
Description: 4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)